



Esperion Therapeutics, Inc.
 Investor Relations Department
 3891 Rancho Drive
 Suite 150
 Ann Arbor, MI 48108
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: ESPR

Last Trade:	57.76
Trade Time:	4:00 PM ET Dec 14, 2017
Change:	0.63 ↑ (+1.103%)
Day Range	56.71 - 61.38
52-Week Range	10.71 - 65.20
Volume	772,328

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 14, 2017 [Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors](#)
- Dec 1, 2017 [Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Nov 13, 2017 [Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference](#)
- Nov 9, 2017 [Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference](#)
- Nov 7, 2017 [Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 22, 2017 [Annual Report \(10-K\)](#)
- Mar 6, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 8, 2017 [Quarterly Report \(10-Q\)](#)
- May 4, 2017 [Quarterly Report \(10-Q\)](#)